---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-22-000137"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T21:00:07.199085+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q3 revenue $156.4M, GAAP EPS $(0.43); cuts FY22 guidance; acquires Gateway Genomics for $67.5M

## Summary
- Revenue $156.4M (-2% YoY); GAAP EPS $(0.43), adjusted EPS $(0.19).
- GeneSight volumes +34% YoY; hereditary cancer volumes +4% YoY; total testing volumes +12% ex-divestitures.
- Acquired Gateway Genomics for $67.5M cash plus up to $32.5M earnout; Gateway expected to be accretive in 2024.
- FY2022 revenue guidance cut to $668-672M (prev. $670-700M); adjusted EPS guided to $(0.35)-$(0.30).
- Quarter-end cash $259.2M, no debt; operating cash flow -$2M.

## SEC filing metadata
- accession: 0000899923-22-000137
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992322000137/0000899923-22-000137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992322000137/mygn-20221101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-22-000137
- JSON: https://secwatch.observer/filing/0000899923-22-000137.json
- Plain text: https://secwatch.observer/filing/0000899923-22-000137.txt

## Key facts
- Earnings Releases
  MYRIAD GENETICS INC reported the three months ended September 30, 2022 results: revenue $156.4 million, EPS $(0.43).
  - Period: the three months ended September 30, 2022
  - Revenue: $156.4 million
  - EPS: $(0.43)
  - Result: reported results
  source text: Myriad Genetics Reports Third Quarter Financial Results Highlights: • Revenue of $156.4 million for the quarter ended September 30, 2022. ▪ Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3 million), change of estimates 1 ($5.3 million). ▪ Third quarter testing volumes, excluding divested businesses, grew 12% year-over-year. Hereditary cancer testing volume continued to improve in 2022 and grew 4% year-over-year in the third quarter. GeneSight volumes grew 34% over third quarter of 2021. ▪ We believe that the underlying pricing of Myriad testing products remains stable, notwithstanding that average selling price overall was negatively impacted by currency translations, change of estimates and a non-recurring milestone payment in the third quarter. • Diluted GAAP earnings per share (EPS) were $(0.43) and adjusted EPS were $(0.19) in the third quarter of 2022 .
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992322000137/0000899923-22-000137-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.